Skip to main content

Advertisement

Table 2 Gametocytaemia and mosquito level outcomes by treatment group and study.

From: Reduction of transmission from malaria patients by artemisinin combination therapies: a pooled analysis of six randomized trials

Study & country Treatment Parasitological treatment failure (%) Mean AUC per day % gametocyte slide-positive at transmission experiment N transmission experiments (patients) % mosquitoes infected* Mean oocyst density
1. Gambia Targett 2001 [22] CQ 59.3 67.4 17.4 21 13.4 3.1
  SP 12.9 117.6 37.8 57 5.5 0.5
  SP-AS1 3.8 3.4 16.3 22 8.7 0.5
  SP-AS3 0 11.9 25.4 12 18.8 5.2
  all 23.9 66.2 27.6 112 9.0 1.6
2. Gambia Targett 2001 [22] SP -† -† 64.0 20 10.7 1.5
  SP-AS3    13.4 20 6.1 0.3
  all    23.3 40 8.4 0.9
3. Gambia Drakeley 2004 [20] CQ 73.5 58.7 49.5 35 13.1 3.9
  CQ-AS 54.7 36.4 26.5 32 5.2 0.4
  all 59.6 42.0 32.1 67 9.3 2.1
4. Gambia Hallett 2006 [13] CQ 73.5 81.1 54.2 17 5.5 0.8
  SP 57.4 216.2 89.6 30 2.7 0.2
  CQ-SP 19.4 134.8 61.3 20 4.6 1.1
  all 46.0 147.7 64.8 67 4.0 0.6
5. Gambia Sutherland 2005 [21] CQ-SP 19.0 44.6 41.7 22 3.0 0.1
  AL 15.0 2.9 5.8 39 0.1 0.0
  (Coartem)       
  all 15.7 9.9 12.2 61 1.2 0.1
6. Kenya Bousema 2006 [19] SP 54.1 19.2 37.2 71 7.0 -‡
  SP-AQ 13.4 11.2 31.6 41 4.7  
  SP-AS3 17.9 3.9 9.6 41 2.6  
  AL 4.1 2.3 6.8 29 4.1  
  (Coartem)       
  all 25 9.1 21.7 182 5.0  
  1. Means are arithmetic. CQ = chloroquine, SP = sulphadoxine-pyrimethamine, AS1 = 1-dose artesunate, AS-3 = 3-dose artesunate, AL = artemether-lumefantrine (Coartem), AQ = amodiaquine. AUC = area under the gametocyte density-time curve. For numbers of patients contributing to parasitology outcomes see Table 1.
  2. * mean of percentages per patient
  3. † follow up was only 14 days compared to 28 days in the other studies. Therefore study 2 was not included in analyses involving parasitological failure or the AUC
  4. ‡ Oocyst count data was not collected